Indicators
Indicators
Value
Direction
MACD(12,26,9)
0.079
Buy
RSI(14)
62.369
Neutral
STOCH(KDJ)(9,3,3)
75.495
Neutral
ATR(14)
1.231
High Vlolatility
CCI(14)
86.732
Neutral
Williams %R
19.027
Overbought
TRIX(12,20)
0.809
Sell
StochRSI(14)
45.149
Sell
Immunome Inc
IMNM18.300USD
-0.350-1.88%
Close 11/25, 16:00（ET）Quotes delayed by 15 min
1.68BMarket Cap
LossP/E TTM
TradingKey Stock Score
Overall Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Peer Comparison
TradingKey Stock Score of Immunome Inc
Currency: USD Updated: 2025-11-25Key Insights
The company's fundamentals are relatively very healthy. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. The company is performing strongly in the stock market, with strong fundamentals and technicals supporting the momentum. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Immunome Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Analyst Rating
Based on
12
analysts
Buy
Current Rating
24.727
Target Price
+32.59%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Immunome Inc Highlights
StrengthsRisks
Immunome, Inc. is a biotechnology company engaged in developing targeted cancer therapies. The Company's portfolio pursues each target with a modality appropriate to its biology, including immunotherapies, radioligand therapies and Antibody-Drug Conjugates (ADCs). Its memory B cell hybridoma technology allows for the screening and functional characterization of novel antibodies and targets. Its programs include Oncology (IMM-ONC-01), LU FAP, and SARS-CoV-2 (IMM-BCP-01). The oncology program is an antibody (IMM-ONC-01) against interleukin-38 (IL-38) a novel immune modulator for the treatment of various solid tumors. Its Targeted Effector platform uses small molecule ligands to selectively deliver drug payloads to diseased cells. It also operates AL102 and related drug candidate AL101. AL102 is an investigational small molecule gamma secretase inhibitor being evaluated in the Phase III for the treatment of desmoid tumors. AL102 is a potential once-daily oral treatment for desmoid tumors.
Growing
The company is in a growing phase, with the latest annual income totaling USD 9.04M.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 9.04M.
Undervalued
The company’s latest PE is -6.18, at a low 3-year percentile range.
Institutional Selling
The latest institutional holdings are 84.54M shares, decreasing 1.79% quarter-over-quarter.
Held by Steven Cohen
Star Investor Steven Cohen holds 4.82M shares of this stock.
Financial Health
Currency: USD Updated: 2025-11-25The company's current financial score is 7.26, which is higher than the Biotechnology & Medical Research industry's average of 6.92. Its financial status is robust, and its operating efficiency is low. Its latest quarterly revenue reached 0.00, representing a year-over-year decrease of 100.00%, while its net profit experienced a year-over-year decrease of 21.99%.
Score
Financials
9.52
Key Metrics
Cash and cash equivalents
Total assets
Total liabilities
Free cash flow
Relevant data have not been disclosed by the company yet.
Quality of Earnings
8.13
Operational Efficiency
2.70
Growth Potential
8.61
Shareholder Returns
7.32
Immunome Inc's Company Valuation
Currency: USD Updated: 2025-11-25The company’s current valuation score is 5.79, which is lower than the Biotechnology & Medical Research industry's average of 7.05. Its current P/E ratio is -6.18, which is -82.96% below the recent high of -1.05 and -1.91% above the recent low of -6.30.
Score
Valuation Dimensions
P/E
P/B
P/S
P/CF
Industry Ranking 43/405
Relevant data have not been disclosed by the company yet.
Earnings Forecast
Currency: USD Updated: 2025-11-25The company’s current earnings forecast score is 8.67, which is higher than the Biotechnology & Medical Research industry's average of 8.02. The average price target for Immunome Inc is 22.00, with a high of 38.00 and a low of 18.00.
Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Analyst Rating
Based on
12
analysts
Buy
Current Rating
24.727
Target Price
+32.59%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
523
Total
5
Median
6
Average
Company name
Ratings
Analysts
Immunome Inc
IMNM
12
CRISPR Therapeutics AG
CRSP
30
Ionis Pharmaceuticals Inc
IONS
25
argenx SE
ARGX
25
Intellia Therapeutics Inc
NTLA
25
IQVIA Holdings Inc
IQV
25
1
2
3
...
105
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Relevant data have not been disclosed by the company yet.
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Price Momentum
Currency: USD Updated: 2025-11-25The company’s current price momentum score is 9.34, which is higher than the Biotechnology & Medical Research industry's average of 7.08. Sideways: Currently, the stock price is trading between the resistance level at 20.09 and the support level at 15.57, making it suitable for range-bound swing trading.
Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Indicators
The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.
This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.
Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.
Moving Average
Indicators
Value
Direction
MA5
18.136
Buy
MA10
17.775
Buy
MA20
16.901
Buy
MA50
14.774
Buy
MA100
12.362
Buy
MA200
10.416
Buy
Institutional Confidence
Currency: USD Updated: 2025-11-25The company’s current institutional recognition score is 10.00, which is higher than the Biotechnology & Medical Research industry's average of 5.14. The latest institutional shareholding proportion is 92.66%, representing a quarter-over-quarter decrease of 6.85%. The largest institutional shareholder is The Vanguard, holding a total of 4.88M shares, representing 5.32% of shares outstanding, with 10.78% increase in holdings.
Score
Institutional Shareholding
Relevant data have not been disclosed by the company yet.
Shareholder Activity
Name
Shares Held
Chg %
Fidelity Management & Research Company LLC
T. Rowe Price Investment Management, Inc.
BlackRock Institutional Trust Company, N.A.
Redmile Group, LLC
Enavate Sciences GP, LLC
EcoR1 Capital, LLC
Opaleye Management Inc.
1
2
Risk Assessment
Currency: USD Updated: 2025-11-25The company’s current risk assessment score is 4.10, which is higher than the Biotechnology & Medical Research industry's average of 3.47. The company's beta value is 2.11. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets.
Score
Beta vs S&P 500 index
2.11
VaR
+8.62%
240-Day Maximum Drawdown
+60.40%
240-Day Volatility
+78.50%
Return
Best Daily Return
60 days
+16.40%
120 days
+16.40%
5 years
+75.56%
Worst Daily Return
60 days
-10.65%
120 days
-10.65%
5 years
-20.72%
Sharpe Ratio
60 days
+3.42
120 days
+2.29
5 years
+0.41
Risk Assessment
Maximum Drawdown
240 days
+60.40%
3 years
+79.66%
5 years
+94.89%
Return-to-Drawdown Ratio
240 days
+0.52
3 years
+1.53
5 years
-0.04
Skewness
240 days
+0.54
3 years
+1.19
5 years
+2.57
Volatility
Realised Volatility
240 days
+78.50%
5 years
+112.27%
Standardised True Range
240 days
+4.08%
5 years
+5.47%
Downside Risk-Adjusted Return
120 days
+460.60%
240 days
+460.60%
Maximum Daily Upside Volatility
60 days
+71.06%
Maximum Daily Downside Volatility
60 days
+48.46%
Liquidity
Average Turnover Rate
60 days
+0.99%
120 days
+1.24%
5 years
--
Turnover Deviation
20 days
-44.73%
60 days
-26.54%
120 days
-8.24%
Peer Comparison
Biotechnology & Medical Research
Immunome Inc
IMNM
7.70 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
IQVIA Holdings Inc
IQV
8.83 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Zymeworks Inc
ZYME
8.64 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
NewAmsterdam Pharma Company NV
NAMS
8.60 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
MDGL
8.57 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Dynavax Technologies Corp
DVAX
8.56 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
View more
FAQs
How does TradingKey generate the Stock Score of Immunome Inc?
The TradingKey Stock Score provides a comprehensive assessment of Immunome Inc based on 34 indicators derived from over 100 underlying data points. These indicators are categorised into six key dimensions: financial health, company profile, earnings forecasts, price momentum, institutional confidence, and risk assessment, collectively providing investors with a thorough analysis of Immunome Inc’s performance and outlook.
How do we generate the financial health score of Immunome Inc?
To generate the financial health score of Immunome Inc, we analyse various key financial indicators across several core dimensions, including financial fundamentals, earnings quality, operational efficiency, growth potential, and shareholder returns. By integrating these comprehensive data, the financial health score not only reflects Immunome Inc's overall stability, operational efficiency, and growth potential but also captures the investment returns delivered to shareholders. This score aims to support rational decision-making for investors and other stakeholders. A higher score indicates a better financial health of Immunome Inc.
How do we generate the company valuation score of Immunome Inc?
To generate the company valuation score of Immunome Inc, we use several key financial ratios, including P/E, P/B, P/S, and P/CF. These metrics compare Immunome Inc’s market value to its earnings, assets, sales, and cash flow, serving as core indicators for assessing company value. By analysing these ratios in an all-round manner, the valuation score reflects not only the market’s current perception of Immunome Inc’s value but also its future profitability and growth potential, thereby supporting more informed investment decisions. A higher score indicates a fairer valuation of Immunome Inc.
How do we generate the earnings forecast score of Immunome Inc?
To calculate the earnings forecast score of Immunome Inc, we consider various key indicators such as analyst ratings, financial forecasts, support and resistance levels, and peer comparisons:Current ratings and price targets directly reflect analysts’ expectations, while the upside space indicates their views on the stock’s growth potential.Financial metrics like earnings per share (EPS), revenue, net income, and earnings before interest and taxes (EBIT) are core measures for assessing profitability.By analysing the high, median, and low ranges of the target price, we can identify price trends and determine key support and resistance levels.Comparing these indicators against peers provides context for the stock’s performance and helps
anchor more realistic expectations.These factors together form a comprehensive earnings forecast score that accurately reflects the stock’s expected financial performance and growth potential. A higher score suggests that analysts have a more optimistic outlook on Immunome Inc’s future.
How do we generate the price momentum score of Immunome Inc?
When generating the price momentum score for Immunome Inc, we examine momentum indicators including support and resistance levels as well as volume metrics.Support levels represent price points where buying interest is strong enough to prevent further declines, while resistance levels indicate prices where selling pressure may hinder upward movement. By analysing typical price volume alongside total volume, we assess overall market activity and liquidity. These indicators help identify price trends and potential shifts, enabling more accurate predictions of future earnings.This comprehensive approach can reflect market sentiment and enable rational forecasts of Immunome Inc’s prices. A higher score indicates a more stable short-term price trend for Immunome Inc.
How do we generate the institutional confidence score of Immunome Inc?
To generate the institutional confidence score of Immunome Inc, we analyse both the proportion of shares held by institutions and the number of shares they own. A higher institutional ownership percentage indicates strong confidence of professional investors, which is generally a positive signal about Immunome Inc’s potential. By examining the number of shares held, we gain deeper insight into institutions’ commitment and attitude toward the stock, as institutional investors typically conduct thorough analysis before making investment decisions. Understanding institutional confidence helps us refine earnings forecasts and provides a more reliable perspective on the company’s future performance and market stability. A higher score indicates greater institutional endorsement of Immunome Inc.
How do we generate the risk management score of Immunome Inc?
To assess the risk management score of Immunome Inc, we examine multiple key indicators related to returns, risk, volatility, and liquidity.The highest and lowest daily returns reflect the potential size of gains and losses, while the Sharpe ratio measures risk-adjusted return performance. On the risk side, we analyse maximum drawdown and the return-to-drawdown ratio to identify extreme loss scenarios. Skewness helps assess the distribution of returns and whether performance may be biased. Volatility indicators—such as realised volatility and standardised true range—reveal price fluctuations. Downside risk-adjusted returns provide insight into potential losses and gains. Lastly, liquidity metrics like average turnover rate and turnover deviation indicate how actively the stock is traded.These indicators together provide a multi-dimensional understanding of Immunome Inc’s risk-return profile, serving as core factors of the risk management score. A higher score indicates lower risk on the side of Immunome Inc.
